SecBot SecBot
6-K ·Filed Sep 1, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 5/10
Horizonmonths Processed2mo ago SEC0001654954-26-007986
Notable filing: 6-K
Actionable Insight • Neutral

The deal is strategically positive for AstraZeneca's lung cancer franchise but the $600M upfront cost and lack of near-term revenue impact make the immediate stock reaction muted. Monitor the FDA decision on the 1st-line sNDA and US launch execution in Q4 2026 for catalysts. The transaction's size (~0.6% of market cap upfront) is manageable for a $251B company, limiting downside risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

AZN drug pipeline →

sunvozertinib

● Neutral Named in this 6-K
Impact
Phase
Approved (China); Phase 3 first-line data filed for approval
Time to market
Already approved in China (the 6-K calls it an "approved asset"); US/EU timeline not yet announced by AstraZeneca
Next catalyst
None dated

What to watchWatch for (1) the China first-line indication decision and (2) any AstraZeneca regulatory submissions for Zegfrovy in the US/EU, plus whether AZN pays out the up-to-$900M milestones to Dizal, milestone payouts signal successful global filings. Treat this as franchise-building context for AZN's lung-cancer portfolio (Tagrisso et al.), not a standalone share-price event: the $600M upfront is tiny relative to AZN's market cap.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$162.22
T+0 close · Sep 1, 2026 · via day close
Latest settled
−0.46%
T+20 · $161.47 · next T+60 in 8d
Vs SPY
−0.57%
α at T+20
Latest observation
+14.90%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $162.22entry
  2. T+1 · 3mo ago −0.58%α −1.02% · $161.28
  3. T+5 · 2mo ago −3.25%α −3.33% · $156.94
  4. T+20 · 7w ago −0.46%α −0.57% · $161.47
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca completed its previously announced exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC with exon 20 insertion mutations. AstraZeneca paid $600M upfront with up to $900M in milestones plus tiered royalties, gaining worldwide rights to a drug already approved in the US and China for 2nd-line treatment and under FDA review for 1st-line use. The deal strengthens AstraZeneca's lung cancer portfolio but the $600M upfront and potential $1.5B total consideration represent a material cash outlay with no near-term revenue contribution, and the company stated it does not impact 2026 financial guidance.

Key Facts

  • AstraZeneca completed an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC.
  • AstraZeneca made a $600M upfront payment to Dizal, with up to $900M in additional milestone payments and tiered royalties on global sales.
  • Zegfrovy is already approved in the US and China for 2nd-line treatment of NSCLC with EGFR exon 20 insertion mutations.
  • A supplemental NDA for 1st-line use has been accepted by the FDA, supported by positive Phase III WU-KONG28 trial data.
  • AstraZeneca will launch Zegfrovy in the US during Q4 2026 for the 2nd-line indication.
  • The transaction does not impact AstraZeneca's financial guidance for 2026.

Financial Impact

$600M upfront payment plus up to $900M in development, regulatory, and sales milestones, plus tiered royalties on global sales

cashr&d expensefuture revenue

Risk Factors

  • FDA decision on 1st-line sNDA is pending and could be delayed or negative
  • Commercial execution risk for US launch in Q4 2026
  • Milestone payments of up to $900M are contingent on development and sales outcomes
  • Competition from other EGFR exon 20 targeting therapies may limit peak sales

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007986
Document: 0001654954-26-007986-index-headers.html0001654954-26-007986
Document: 0001654954-26-007986-index.html0001654954-26-007986
Document: 0001654954-26-007986.txt0001654954-26-007986

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026